Three-decade neurological and neurocognitive follow-up of HIV-1-infected patients on best-available antiretroviral therapy in Finland

Por Heikinheimo, T, Poutiainen, E, Salonen, O, Elovaara, I, Ristola, M
Publicado no BMJ Open (2015)

Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells

Por Airas, L, Saraste, M, Rinta, S, Elovaara, I, Huang, Y-H, Wiendl, H
Publicado em 2008

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

Por Andersen, O, Elovaara, I, Farkkila, M, Hansen, H, Mellgren, S, Myhr, K, Sandberg-Wollheim, M, Soelberg, S
Publicado em 2004

Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations

Por Kristjansdottir, G, Sandling, J K, Bonetti, A, Roos, I M, Milani, L, Wang, C, Gustafsdottir, S M, Sigurdsson, S, Lundmark, A, Tienari, P J, Koivisto, K, Elovaara, I, Pirttilä, T, Reunanen, M, Peltonen, L, Saarela, J, Hillert, J, Olsson, T, Landegren, U, Alcina, A, Fernández, O, Leyva, L, Guerrero, M, Lucas, M, Izquierdo, G, Matesanz, F, Syvänen, A-C
Publicado em 2008